Search

everythinglearnresearchcommunity

for

Search:↓

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

A user purchased an expensive hair loss treatment called Follicopeptide, which many others in the conversation believe to be a scam, suggesting instead the use of proven treatments like minoxidil and finasteride. Some users report positive effects from Follicopeptide, but skepticism remains high due to lack of transparency about its ingredients and the company's credibility.

The user is pleased with their hair growth results after using oral minoxidil (2.5mg) for 3 months and finasteride (1mg) for 4 months, despite experiencing significant shedding initially. They prefer oral treatments over topical due to convenience and concerns about toxicity to pets.

COVID and COVID vaccination can trigger hair loss, primarily telogen effluvium, due to stress and immune system activation. Proper diagnosis and addressing factors like nutrition and stress are crucial for recovery.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The user shared a successful hair regrowth journey using finasteride and oral minoxidil, starting in 2020. They experienced significant improvement without side effects and stopped microneedling due to a fear of needles.

A 41-year-old doctor shared his positive experience with a 4,100 graft hair transplant, highlighting the importance of a skilled doctor for a natural hairline. He mentioned a confidence boost and the occasional use of finasteride post-transplant.

The user is considering trying finasteride again for hair loss despite past side effects like tender nipples and concerns about mental health impacts. They are advised to consult a doctor and consider topical or low-dose finasteride.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Eating pumpkin seeds is unlikely to cause significant hormonal changes or side effects like decreased libido or erectile dysfunction. Pumpkin seeds are not an effective substitute for finasteride or dutasteride in treating hair loss.

Creatine monohydrate's potential link to hair loss, with mixed opinions on its effects. Treatments like minoxidil, finasteride, and RU58841 are discussed.

The user is experiencing hair loss at Norwood 2.5 and is using minoxidil, finasteride, and vitamins, noticing minimal regrowth after 8 months. They are considering using a dermaroller but are unsure of its effectiveness.

Microneedling alone may slightly slow hair loss but doesn't promote regrowth or improve hair density. Combining treatments like finasteride or minoxidil with microneedling may yield better results.

Oleic acid, microneedling, and emu oil are discussed as potential hair growth treatments, with some users expressing skepticism about their effectiveness. Minoxidil and finasteride are recommended as current reliable treatments until more proven solutions are available.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

The user started on Finasteride, switched to Dutasteride, and is considering microneedling but was advised against it by their hair surgeon due to potential scalp issues affecting a planned hair transplant. Other users suggest alternatives like Minoxidil, PRP, and avoiding microneedling due to the risk of scar tissue impacting transplant results.

The user experienced positive results with topical Minoxidil 6%, Finasteride 0.3%, and Tretinoin 0.025% over two months, with improved hair density and no significant side effects except for a dry, itchy scalp. The user uses a biotin shampoo and conditioner to manage scalp issues and applies the treatment once daily.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

Switching from finasteride to dutasteride can cause significant hair shedding if done abruptly. It's recommended to overlap both treatments and gradually taper off finasteride to minimize shedding.

A 24-year-old considering a hair transplant is currently using dutasteride for hair loss. They are unsure about proceeding with the transplant due to concerns about future hair loss and the need to shave their head for the procedure.

The conversation discusses a five-year hair maintenance routine involving microneedling, minoxidil, finasteride, biotin, and thickening shampoo. Opinions vary, with some seeing maintaining hair as a success and others expecting more visible results.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

A new topical finasteride has been approved in France, providing an alternative to oral finasteride with potentially fewer side effects. Users discuss the pros and cons of topical versus oral treatments, with some opting to create their own solutions to save money.

The user shared their journey with hair loss, using minoxidil initially, then adding microneedling and finasteride, and finally undergoing a hair transplant. They expressed regret for not using finasteride earlier due to fear of side effects and found the combination of treatments effective in the end.

A user shared their 7-month progress after a hair transplant, using dutasteride and minoxidil to maintain native hair. The transplant was done in Juarez, Mexico, and the user noted that medication is still necessary to prevent further hair loss.

Microneedling can cause skin shedding and inflammation, with some users adjusting needle size or frequency to reduce these effects. Some users combine microneedling with treatments like minoxidil, while others prefer smaller needles or alternative treatments like dutasteride.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.